Gelteq Limited (GELS)
| Market Cap | 20.67M |
| Revenue (ttm) | 95,618 |
| Net Income (ttm) | -2.37M |
| Shares Out | 9.44M |
| EPS (ttm) | -0.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,217 |
| Open | 2.130 |
| Previous Close | 2.150 |
| Day's Range | 2.050 - 2.300 |
| 52-Week Range | 1.420 - 5.500 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 15, 2025 |
About GELS
Gelteq Limited focuses on developing, testing, and commercializing white label gel-based delivery solutions for humans and animals. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Caulfield, Australia. [Read more]
Financial Performance
In 2024, Gelteq's revenue was 143,313, a decrease of -58.21% compared to the previous year's 342,901. Losses were -3.55 million, 1.14% more than in 2023.
Financial numbers in AUD Financial StatementsNews
Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug
Approval grants Gelteq fast track pathway for drug and entrance into the animal pharmaceuticals space Approval grants Gelteq fast track pathway for drug and entrance into the animal pharmaceuticals sp...
Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white labe...
Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand
Healthy Extracts expands order after high demand for Gelteq's collagen and Mynus sugar blocker gels Healthy Extracts expands order after high demand for Gelteq's collagen and Mynus sugar blocker gels
Gelteq Announces 400,000 Units Enter into Production in November 2024
NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label gel-ba...
Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white labe...
Gelteq Limited Closes US$5.2 Million Initial Public Offering
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible...
Gelteq Limited Prices US$5.2 Million Initial Public Offering
Company anticipates commencement of trading on Nasdaq effective October 29, 2024 under the symbol “GELS” Company anticipates commencement of trading on Nasdaq effective October 29, 2024 under the symb...